Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial

Journal of Urology

Volumn 173, Issue 3, 2005, Pages 746-751

  Pinsky, Paul F ^a,b   Andriole, Gerald L ^c   Kramer, Barnett S ^b   Hayes, Richard B ^a   Prorok, Philip C ^a   Gohagan, John K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biopsy; Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER SCREENING; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

EID: 13744253438     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000152697.25708.71     Document Type: Conference Paper

References (10)

1. Howe, H. L., Wingo, P. A., Thun, M. J., Ries, L. A., Rosenberg, H. M., Feigal, E. G. et al: Annual report to the nation on the status of cancer (1973-1998), featuring cancers with recent increasing trends. J Natl Cancer Iust, 93: 824, 2001
2. Jacobsen, S. J., Katusic, S. K., Bergstralh, E. J., Oesterling, J. E., Ohrt, D., Klee, G. G. et al: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA, 274: 1445, 1995
3. Hankey, B. F., Feuer, E. J., Clegg, L. X., Hayes, R. B., Legler, J. M., Prorok, P. C. et al: Cancer surveillance series: interpreting trends in prostate cancer - part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst, 91: 1017, 1999
4. Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., Crawford, E. D. et al: Design of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials, suppl., 21: 273S, 2000
5. Crawford, E. D., Leewansangtong, S., Goktas, S., Holthaus, K. and Baier, M.: Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate, 38: 296, 1999
6. Kaplan, E. L. and Meier, P.: Non-parametric estimation from incomplete observations. J Am Statist Assoc, 53: 457, 1968
7. Cox, D. R.: Regression models and life tables (with discussion). J R Stat Soc B, 34: 187, 1972
8. Smith, D. S., Bullock, A. D. and Catalona, W. J.: Racial differences in operating characteristics of prostate cancer screening tests. J Urol, 158: 1861, 1997
9. Catalona, W. J., Antenor, J. A. and Roehl, K. A.: Screening for prostate cancer in high risk populations. J Urol, 168: 1980, 2002
10. Eastham, J. A., Riedel, E., Scardino, P. T., Shike, M., Fleisher, M., Schatzkin, A. et al: Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA, 289: 2695, 2003